BIND Therapeutics To Report Second Quarter 2015 Financial Results On August 6, 2015

CAMBRIDGE, Mass.--(BUSINESS WIRE)--BIND Therapeutics, Inc. (NASDAQ: BIND), a clinical-stage nanomedicine company developing targeted and programmable therapeutics called Accurins^TM, today announced it will host a conference call and live audio webcast on August 6, 2015, at 8:30 a.m. ET to report second quarter 2015 financial results.

To access the conference call, please dial (877) 312-5844 (domestic) or (253) 237-1152 (international) at least five minutes prior to the start time and refer to conference ID 96619516. A live audio webcast of the call will also be available on the Investors & Media section of the Company’s website, www.bindtherapeutics.com. An archived webcast will be available on the Company’s website approximately two hours after the event.

About BIND Therapeutics

BIND Therapeutics is a clinical-stage nanomedicine company developing Accurins™, its novel targeted therapeutics. BIND is leveraging its Medicinal Nanoengineering® platform to develop a pipeline of Accurins, initially in oncology, as well as Accurins in collaboration with biopharmaceutical companies.

BIND has announced ongoing collaborations with Pfizer Inc., AstraZeneca AB, F. Hoffmann-La Roche Ltd., Merck (known as Merck Sharp & Dohme outside the United States and Canada) and Macrophage Therapeutics (a subsidiary of Navidea Biopharmaceuticals) to develop Accurins based on their proprietary therapeutic payloads and targeting ligands. For more information, please visit the Company’s website at www.bindtherapeutics.com.